The company


About us

iosBio is a UK-based biotechnology company developing a ground-breaking oral platform that could revolutionize the way vaccines are manufactured, distributed and delivered. Our current focus is an oral vaccine for Covid-19, which has started clinical trials, an oral version of the seasonal influenza vaccine in preclinical studies and several further vaccines and therapies in discovery.

We believe that the future of immunization – no needles, no healthcare professionals, no queues and no risk of cross infection – is now possible, and we are working to make it a reality.

Our vision

iosBio’s vision is a world in which getting vaccinated is as fast, cheap and easy as taking a paracetamol. A world in which no one has to fall victim to disease simply because they couldn’t make it to a clinic, or because they were born in a country without the infrastructure for reliable refrigeration. The technology of immunization is reaching new levels of innovation and efficacy all the time – we offer a delivery mechanism to match.

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery


Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

Contact us on info@iosbio.com / 01444 241911 or fill out the form below.

    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.

    As the coronavirus pandemic rages on around the world, scientists are working day and night to create safe and effective vaccines that will allow life to return to normal. Although great leaps forward have been made, we are already seeing the supply chain and logistical problems of injectable vaccines that require cold or ultra cold chain storage. And as further mutations of the virus continue to emerge, the ability to tweak and readminister vaccines becomes ever more crucial.

    iosBio has partnered with US pharmaceutical company ImmunityBio to create OraPro-Covid-19, deploying our ground-breaking oral vaccine delivery platform with the aim of creating a Covid-19 vaccine that can be sent by post and swallowed at home.

    close

    The global seasonal influenza market is forecast to be worth $4.3bn by 2025. This figure is unsurprising considering the enormous economic costs of flu each year.

    On average, the total estimated annual economic burden of influenza to the US healthcare system and society is $11.2 billion, comprising $3.2 billion in direct medical costs and $8 billion in indirect costs. The CDC (Centre for Disease Control and Prevention) recommends that every person from the age of six months onwards has a flu vaccine, but actual vaccination coverage hovers around 50%

    In the UK, six million working days are lost to seasonal influenza in an average winter, yet uptake amongst the under-65s has been steadily declining in recent years. Many cite difficulties with getting an appointment at their GP’s surgery, where the vast majority of flu jabs are still administered.

    close

    Zika virus disease is caused by a virus transmitted primarily by mosquitoes, as well as through sexual contact and from mother to fetus during pregnancy. Zika infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, and is also associated with other complications including preterm birth and miscarriage. An increased risk of neurologic complications is associated with Zika virus infection in adults and children, including Guillain-Barré syndrome, neuropathy and myelitis.

    From the 1960s to 1980s, rare sporadic cases of human infections were found across Africa and Asia, typically accompanied by mild illness. The first recorded outbreak of Zika virus disease was reported from the Island of Yap in Micronesia in 2007. This was followed by a large outbreak of Zika virus infection in French Polynesia in 2013 and other countries and territories in the Pacific. In March 2015, Brazil reported a large outbreak of rash illness, soon identified as Zika virus infection, and later that year confirmed to be associated with microcephaly and Guillain-Barré syndrome.

    close